ReviewCNS drugs2010
Nervous system effects of antituberculosis therapy.
Review in CNS drugs, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 108 citations in OpenAlex.
- Characteristics of isoniazid-induced psychosis: a systematic review of case reports and case series.European journal of clinical pharmacology · 2024Pooled it
- Prevalence of neurotoxicity symptoms among postpartum women on isoniazid preventive therapy and efavirenz-based treatment for HIV: an exploratory objective of the IMPAACT P1078 randomized trial.BMC pregnancy and childbirth · 2023Trial
- Wernicke Encephalopathy as a Rare Complication of Antituberculosis Treatment: A Case Report.Cureus · 2026Article
- Homeostasis of Gut Microbiota Protects against Susceptibility to Fungal Pneumonia.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- The 3 HP regimen for tuberculosis preventive treatment: safety, dosage and related concerns during its large-scale implementation in countries like India.The Lancet regional health. Southeast Asia · 2024Review
- Article
- Role of the IL8 rs4073 polymorphism in central nervous system toxicity in patients receiving multidrug-resistant tuberculosis treatment.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2024Article
- Drugs with a negative impact on cognitive functions (Part 2): drug classes to consider while prescribing in CKD patients.Clinical kidney journal · 2023Review
- Safety and Tolerability of Antimicrobial Agents in the Older Patient.Drugs & aging · 2023Review
- Cognitive Impairment in Tuberculous Meningitis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Management of Medication-Induced Psychiatric Disorders.Indian journal of psychiatry · 2022Article
- Pyridoxine in isoniazid-induced psychosis.Sudanese journal of paediatrics · 2022Article
- Host Bioenergetic Parameters Reveal Cytotoxicity of Antituberculosis Drugs Undetected Using Conventional Viability Assays.Antimicrobial agents and chemotherapy · 2021Article
- Population Pharmacokinetics of Cycloserine and Pharmacokinetic/Pharmacodynamic Target Attainment in Multidrug-Resistant Tuberculosis Patients Dosed with Terizidone.Antimicrobial agents and chemotherapy · 2020Article
- Incidence of adverse reactions caused by first-line anti-tuberculosis drugs and treatment outcome of pulmonary tuberculosis patients in Morocco.Infection · 2020Article
- Safety implications of combined antiretroviral and anti-tuberculosis drugs.Expert opinion on drug safety · 2020Review
- Mania induced by isoniazid preventive therapy during steroid treatment for rheumatoid arthritis and organising pneumonia.BMJ case reports · 2019Article
- Neurological and Psychiatric Adverse Effects of Antimicrobials.CNS drugs · 2019Review
- Cycloserine Population Pharmacokinetics and Pharmacodynamics in Patients with Tuberculosis.Antimicrobial agents and chemotherapy · 2019Article
- Antibiotic Abuse Induced Histopathological and Neurobehavioral Disorders in Mice.Current drug safety · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nervous system toxicity with current antituberculosis pharmacotherapy is relatively uncommon, although the frequency of the usage of antituberculosis therapy requires that physicians be aware of such toxicity. Antituberculosis therapy manifests both central and peripheral nervous system effects, which may compromise patient compliance. Among the traditional forms of first-line antituberculosis therapy, isoniazid is most often associated with nervous system effects, most prominently peripheral neuropathy, psychosis and seizures. Adverse events are reported with other antituberculosis therapies, the most prominent being optic neuropathy with ethambutol and ototoxicity and neuromuscular blockade with aminoglycosides. The second-line agent with the most adverse effects is cycloserine, with psychosis and seizures, the psychosis in particular limiting its usage. Fluoroquinolones are rare causes of seizures and delirium. Newer forms of therapy are under development, but to date no significant neurotoxicity is documented with these agents. Future needs include the development of surveillance mechanisms to increase recognition of nervous system toxicities. It is also hoped that the development of new pharmacogenomic assays will help with the identification of patients at risk for these toxicities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.